**Atrial Fibrillation Inducibility During Cavo-Tricuspid Isthmus
Dependent Atrial Flutter Ablation as a Predictor of Clinical Atrial
Fibrillation. A Meta-analysis**

Jorge Romero, MD;[†] Juan Carlos Diaz, MD;[‡] Luigi Di Biase, MD-PhD;[‡] Saurabh Kumar, BSc(Med)/MBBS, PhD;[†] Usha B. Tedrow, MD, Carolina R Valencia, RN;[‡] Samuel H. Baldinger, MD;[†] Bruce Koplan, MD;[†] Laurence M. Epstein, MD;[†] Roy John, MD, PhD;[†] MSc;[†] Gregory F. Michaud, MD;[†] William G. Stevenson, MD.[†]

[†]*Brigham and Women's Hospital/Harvard Medical School. Boston, Massachusetts, USA*
[‡]*Montefiore Medical Center, Albert Einstein College of Medicine.
Bronx, New York.*

Short title: AF inducibility during ablation of CTI AFL as a predictor of clinical AF

Correspondence: Dr. Jorge Romero or Dr William G. Stevenson, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA – 02115, USA. Telephone: +1857-307-1947; Fax: +1857-307-1944; email: jromerorojas@partners.org or wstevenson@partners.org

Word count:

Author email addresses: jromerorojas@partners.org, jcdiaz1234@hotmail.com, ldibiase@montefiore.org, caro8711@hotmail.com, samuel.baldinger@hotmail.com, rjohn2@partners.org, gfmichaud@partners.org, bkoplan@partners.org, lepstein@partners.org, utedrow@partners.org, skumar15@partners.org.

Disclosures: Dr Di Biase is a consultant for Biosense Webster, Boston Scientific, and St. Jude Medical and has received speaker honoraria/travel from Medtronic, Atricure, EPiEP, and Biotronik. Dr. Kumar is a recipient of the Neil Hamilton Fairley Overseas Research scholarship co-funded by the National Health and Medical Research Council and the National Heart Foundation of Australia; and the Bushell Travelling Fellowship funded by the Royal Australasian College of Physicians and the Postdoctoral Research Fellowship by the American Heart Association. Dr. Tedrow receives consulting fees/honoraria from Boston Scientific Corp. and St. Jude Medical and research funding from Biosense Webster, Inc., and St. Jude Medical. Dr. John receives consulting fees/honoraria from St. Jude Medical. Dr. Michaud receives consulting fees/honoraria from Boston Scientific Corp., Medtronic, Inc., and St. Jude Medical, and research funding from Boston Scientific Corp., and Biosense Webster, Inc. Dr. Stevenson is co-holder of a patent for needle ablation that is consigned to Brigham and Women's Hospital. The remaining authors have no disclosures.

Background: Atrial fibrillation (AF) and cavo-tricuspid isthmus (CTI) dependent atrial flutter (AFL) are two separate entities that coexist in a significant percentage of patients. We sought to investigate whether AF inducibility during CTI AFL ablation predicted the occurrence of AF at follow up after successful AFL ablation.

Methods: A systemic review of Medline, Cochrane, and Embase for all the clinical studies in which assessment of AF inducibility in patients undergoing ablation for CTI AFL was performed. Given the low heterogeneity (i.e. $I^2 < 25$), we used a fixed effect model for our analysis.

Results: A total of 10 studies (4 prospective and 6 retrospective) with a total of 1299 patients (male: 73 %, mean age 59 ± 11 years) fulfilled the inclusion criteria. During a mean follow up period of 23 ± 7.6 months, 407 patients (31%) developed AF during AFL ablation. The overall incidence for new-onset AF during follow-up was 29% (47% in the group with inducible AF vs. 21% in the non-inducible group). The odds ratio (OR) for developing AF after AFL ablation in patients with AF inducibility for all studies combined was 3.72, 95% CI 2.83-4.89 [prospective studies (OR 5.52, 95% CI 3.23-9.41) vs. retrospective studies (OR 3.23, 95% CI 2.35-4.45)].

Conclusion: Although ablation for CTI AFL is highly effective, AF continues to be a long-term risk for individuals undergoing this procedure. AF induced by pacing protocols in patients undergoing CTI AFL predicts for future AF. Inducible AF is a clinically relevant finding that may help guide decisions for long-term anticoagulation after

successful typical AFL ablation especially in patients with elevated CHADS-VASc scores (≥ 2) and in considering prophylactic PVI during CTI AFL ablation.

Keywords: atrial flutter, cavotricuspid isthmus atrial flutter, atrial fibrillation, AF inducibility.

Abbreviations:

AF: atrial fibrillation

AFL: atrial flutter

CTI: cavotricuspid isthmus

LAE: left atrial enlargement

AAD: antiarrhythmic drugs

CA: catheter ablation

CI: confidence interval

LV: left ventricle

LVEF: left ventricular ejection fraction

RFA: radiofrequency ablation

OR: odds ratio

Introduction

The prevalence of atrial fibrillation (AF) and AFL are rising to epidemic proportions with critical effect on health care costs, resource utilization and economic burden. Typical cavotricuspid isthmus (CTI)-dependent AFL is characterized by successful cure by RFA and low risk of recurrence.¹⁻¹⁰ However, AF occurs in 15 to 82% of patients by 6 to 40 months after AFL ablation.^{6, 8, 9, 11-15} Notably, despite having a 6% cumulative incidence of embolic stroke during mean follow-up of 30 months after ablation for CTI AFL, there are scant recommendations for anticoagulation for this population.^{16, 17} The progressive occurrence of AF after AFL ablation has been associated with numerous factors including advanced age, female sex, BMI, prior history of AF, left atrial enlargement (LAE), reduced left ventricular ejection fraction (LVEF), treatment with antiarrhythmic drugs (AAD) before ablation, mitral regurgitation and AF inducibility.¹⁸⁻²³ The significance of AF inducibility has been controversial. In this meta-analysis we assessed the prognostic value of AF inducibility for new development of AF following successful RFA of CTI AFL.

METHODS

Search strategy: We searched PubMed, Embase, and Cochrane Central Register of Clinical Trials (Cochrane Library, Issue 09, 2015) using the terms: “(*typical atrial flutter OR cavotricuspid atrial flutter OR CTI atrial flutter OR CTI AFL OR right sided atrial flutter OR common atrial flutter OR Type I atrial flutter*) AND (*atrial fibrillation inducibility OR AF inducibility OR Afib inducibility*).” Our search was limited to humans

in peer-reviewed journals from 1990 to January 2016. No language restriction was applied. The reference lists of identified articles were also reviewed.

Selection criteria: The studies had to fulfill the following criteria to be included in the analysis: 1) the study was prospectively or retrospectively designed; 2) the population was composed of patients undergoing RFA for typical CTI dependent AFL; 3) AF inducibility was assessed during that procedure; 4) follow up duration was at least six months to determine new development of AF; 5) the study provided enough data to calculate odds ratio (OR).

Data extraction and quality assessment: Two authors (J.R. and J.D) searched the studies and extracted the data independently and in duplicate. Data was extracted using standardized protocol and reporting forms. Disagreements were resolved by consensus. We extracted characteristics of each study including AF inducibility methodology and baseline patient demographics for our analysis. If this information was not readily available, the principal investigator of the particular study was approached to supply pertinent information. The quality and reporting of the studies were assessed using the New-castle-Ottawa Scale.²⁴ Three categories were included in the analysis, with some of them having subcategories for assessment (i.e., *Selection criteria*: 1- Representativeness of the exposed cohort, 2-Selection of non exposed cohort, 3- Ascertainment of exposure, 4- Demonstration that outcome of interest was not present at start of study. *Comparability criteria*: 1- Study controls for the presence of previous AF, 2- Study controls for additional factors. *Outcome*: 1- Assessment of outcome, 2- Was follow up long enough

for outcomes to occur, 3- Adequacy of outcome of controls). Studies were subsequently classified into 1 of 3 categories: (1) high quality: 7-8 points; (2) satisfactory quality: 3–6 points; and (3) unsatisfactory quality: 0–2 points.²⁴

Statistical analysis: Descriptive statistics are presented as means and standard deviations (SD) for continuous variables or number of cases (n) and as percentages (%) for dichotomous and categorical variables. Statistical analysis was performed in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, using Review Manager (RevMan), version 5.3, the Cochrane Collaboration, 2014. Heterogeneity was assessed using the I^2 statistics, which is the proportion of total variation observed among the studies attributable to differences between studies rather than sampling error (chance).²⁵ Data were summarized across treatment arms using the Mantel-Haenszel OR fixed effects model. We considered I^2 less than 25% as low and I^2 greater than 75% as high. The Random-Effects Model of DerSimonian and Laird was used if $I^2 > 25\%$.²⁶ All analyses were performed using the intention-to-treat principle. Likewise, we calculated the incidence of new onset of AF for all patients, with and without AF inducibility during RFA of CTI AFL, detected by ECG, Holter monitoring or event monitor using relative risk (OR) ratios and 95% confidence intervals with the use of the Mantel–Haenszel method. Publication bias was estimated visually by funnel plots.^{26, 27}

Sensitivity Analysis: We further evaluated if the prognostic value of AF inducibility during AFL ablation for the development of AF depended on features of the study design

(prospective vs. retrospective), pacing protocol and duration of follow up. One study excluded due to low sample size was also included in the sensitivity analysis of this meta-analysis to determine if it has any impact on our results. We estimated differences between subgroups according to the tests of interaction.²⁸

RESULTS

Study selection: We identified 720 abstracts, out of which 320 abstracts were screened after removing duplicates. A total of 48 abstracts were retrieved and carefully reviewed for possible inclusion (Figure 1). Fourteen full-text manuscripts were assessed for eligibility. Ten studies (Table 1-2) with a total of 1299 patients fulfilled the inclusion criteria and were included in the present meta-analysis.^{10, 12, 13, 23, 29-34} Four studies were ultimately excluded from the final analysis since they did not meet the inclusion criteria: the studies by Chinitz et al and by Chen et al were excluded from the analysis because AF induction was not performed in all patients.^{35, 36} Although the study published by Katritsis and colleagues met inclusion criteria, we excluded it due primarily to the fact that they reported outcomes with a very small sample size (n: 6).³⁷ Finally the study published by Schneider et al was excluded due to incomplete data to calculate OR.³⁸

Quality assessment: All the studies included in this meta-analysis had good methodological quality indicating “low risk of bias” (Table 3). Nine studies were classified as high quality and only one study was classified as satisfactory quality based on the Newcastle Ottawa Assessment scale using 8 different parameters. Most studies scored poorly on the demonstration that outcome of interest was not present at start of

study. Moreover, a significant amount of patients in each study already had previous documentation of AF. Fifty percent of the studies had a relatively limited follow up period of less than 2 years, which might underestimate the real incidence of AF (Table 3).

Baseline characteristics and data analysis: The prognostic yield of AF inducibility during CTI AFL ablation for the new onset of AF was assessed from ten studies (four prospective and six retrospective) that enrolled a total of 1299 patients [mean age 59 ± 11 years; male: 73%]. All studies included patients who underwent RFA for typical, CTI-dependent AFL. Mean LVEF and LA size were $51 \pm 7\%$ and 38 ± 1 mm, respectively. A history of documented AF prior to the procedure was present on average in 24% of patients (range 0% to 47%). These studies had a mean follow up of 24 ± 8 months (range 13-35 months).

The overall incidence for new-onset AF during follow-up was 29% (47% in the group with inducible AF vs. 21% in the non-inducible group). The odds ratio (OR) for developing AF after AFL ablation in patients with AF inducibility for all studies combined was 3.72, 95% CI 2.83-4.89, $P < 0.00001$. Prospective studies and retrospective studies were analyzed separately. Although there was a trend favoring prospective studies with a stronger OR of 5.52, 95% CI 3.23-9.41, $P > 0.00001$ when compared with retrospective studies (OR 3.23, 95% CI 2.35-4.45, $P < 0.00001$), no statistical difference was noted ($P: 0.09$). The overall heterogeneity among studies was low and hence a fixed effect model was used (Figure 2-3).

Sensitivity analysis: We examined every variable included in the baseline characteristics table (Table 1-2) and no factor was identified with a significant influence on the total and subtotals of this meta-analysis. Albeit, the study of Katritsis and colleagues met inclusion criteria it was excluded due primarily to the fact that they reported outcomes with a very small sample size (n: 6).³⁷ Including this study to the main meta-analysis did not affect our results [OR=3.74 CI (2.85-4.91), P<0.00001 vs. OR=3.72, CI (2.83-4.89), P<0.00001, respectively].

Publication Bias: Funnel plots did not suggest publication bias. As observed in Figure 4 all studies fell inside the triangle and they are evenly distributed on both sides.

DISCUSSION

In light of emerging data that AF inducibility during CTI dependent AFL may be an important prognostic factor for the development of post procedural AF,^{10, 12, 13, 23, 29-34} we systematically examined the prognostic impact of this parameter in all the available studies in the literature. Uniquely, this is the first meta-analysis to our knowledge analyzing these data. Likewise, we included 10 studies with a large group of 1299 patients with a mean follow up of 24 months. The pertinent findings of this study were:

1. This meta-analysis confirms previous observations of a moderately high incidence of symptomatic post AFL ablation AF (29% at 2 years) despite a low recurrence of typical atrial flutter in patients with CTI isthmus conduction block.

2. This meta-analysis suggests that overall, AF inducibility during CTI AFL ablation increases the probability of developing AF by 3.7 fold and 5.5 fold if only prospective studies are analyzed.

Ambulatory monitoring in patients with AFL frequently documents the coexistence of AF.³⁹ Additionally, AFL may become more frequent, stable, or appear for the first time during AAD therapy of AF.⁴⁰ Consequently, the high frequency of AF in patients referred for CTI AFL ablation (29% in the present meta-analysis), and 15 to 82% in prior reports^{6, 8, 9, 11-15} is not unexpected. The mechanistic relation between these 2 arrhythmias is still not well defined. AF has been identified as a common transitional rhythm before the onset of spontaneous CTI AFL after surgical coronary revascularization as well as during the induction of typical AFL by high right atrial pacing.^{41, 42} The transition from AF to AFL was heralded by lengthening lines of functional block, permitting the emergence of a large stable reentrant circuit. These observations suggest a potentially important role of AF in the genesis of CTI AFL. In many patients, interruption of conduction through the CTI may prevent the organization of AF into flutter. The right atrial flutter circuit has been postulated to play a critical role in the initiation and maintenance of AF in some patients.⁴³ AFL is also occasionally observed to spontaneously disorganize into AF during RFA procedures. These observations may explain the absence of recurrent AF in some patients with previous documentation of this rhythm. However, the frequent coexistence of AF and AFL in the population, and the persistent risk of AF in a substantial number of these patients despite successful long-term elimination of AFL, suggest AF as an initial trigger, rather than a consequence, of CTI AFL in our opinion.

Prior studies

Several factors have been previously reported to be associated with future development of AF after CTI AFL ablation. Yet, results from these studies showing the association of other predictors for AF have been variable, particularly the relation of LA size and LV function are limited by variable methods of assessment. Analyzing the available data on the value of LAE and LVEF as predictors of new onset AF after CTI AFL ablation is somewhat cumbersome since these variables are continuous and not dichotomous.¹⁹ On the other hand, it is also difficult to consider “history of AF” as a predictor of a problem that a patient has already experienced. Chen et al, evaluated the HATCH score in the prediction of new-onset AF after RFA of CTI AFL.³⁶ The HATCH (hypertension, age >75 years, transient ischemic attack or stroke, chronic obstructive pulmonary disease, and heart failure) scoring system was originally developed from the Euro Heart Survey of AF⁴⁴ to enable the detection of patients who are at high risk of progression from paroxysmal AF to more sustained forms of AF in the near future. Nearly half of patients with a HATCH score >5 progressed to persistent AF compared with 6% of patients with a HATCH score of 0. The authors demonstrated that the incidence of new-onset AF increased continuously with an increase in HATCH score ($P < 001$).³⁶ The ROC curve for predicting AF after AFL ablation based on the HATCH score was 0.743. At a cutoff point of 2 identified by the ROC curve (sensitivity 51.8%, specificity 84.7%), patients with a HATCH score >2 were more likely to have advanced age, an LAE, and reduced LVEF. Also, as shown by Kaplan- Meier survival analysis, a HATCH score ≥ 2 was associated with a higher incidence of AF than a HATCH score <2 (69% vs. 27%, $P <$

0.001) during mean follow up. Multivariate Cox regression analysis demonstrated that the HATCH score had only a Hazard Ratio (HR) of 1.784; 95% CI 1.352–2.324; $P < 0.001$ along with a low HR for LA diameter (HR 1.27; 95% CI 1.115–1.426; $P < 0.001$).³⁶ AF inducibility in this meta-analysis had a OR of 3.7; 95% CI 2.83–4.89, $P < 0.00001$. Interestingly, Joza et al, elegantly demonstrated that in patients without a documented history of AF, inducibility of AF after AFL ablation is strongly associated with the future development of AF (adjusted HR 15.99; 95%CI 5.10–50.12).³⁰ In contrast, in patients with a documented history of paroxysmal or persistent AF, AF inducibility was not associated with an increased risk of future development of AF (adjusted HR 1.26; 95% CI 0.74–2.14). Furthermore, a documented history of AF was strongly associated with the future development of AF (adjusted HR 9.44; 95% CI 3.61–24.64).³⁰ Hsieh et al demonstrated that positive inducibility correlated with the future development of AF; however, there was no difference among patients who had a history of AF and those who did not. Nonetheless, this conclusion may have been influenced by the fact that inducibility testing was performed before the creation of AFL line.¹⁰

Noticeably, the presence of advanced interatrial block (aIAB), defined as a P-wave duration ≥ 120 ms and biphasic morphology in the inferior leads, has also been associated with an elevated risk of AF after RFA of CTI AFL and no prior history of AF (64.7 vs. 29.4%; $P: 0.001$). In multivariable analysis, aIAB was the strongest predictor of new-onset AF [OR 4.2, 95% confidence interval (CI): 1.9–9.3; $P, 0.001$].⁴⁵ Likewise, more recently intra-atrial conduction delay was also reported to be a significant risk factor for AF following CTI AFL ablation. Antegrade (high right atrium to coronary sinus: HRA-CS) and retrograde (CS-HRA) intra-atrial conduction times and AF inducibility were

assessed in 61 patients undergoing ablation for typical AF. Patients with post-ablation AF had longer intra-atrial conduction times before (98 ± 17 ms vs. 68 ± 20 ms, $P: 0.001$) and after ablation (91 ± 19 ms vs. 73 ± 21 ms, $P: 0.01$) than those without AF. Multivariate analysis revealed that only age, previous AF and intra-atrial conduction delay (>90 ms) were independent predictors of post ablation AF. Patients without a history of AF and with normal intra-atrial conduction had a 3% risk of AF, while patients with both factors had a 90% risk of AF after ablation.²⁹

Clinical Implications

This meta-analysis compares AF inducibility during CTI AFL ablation and the development AF post-ablation. Patient who were inducible for AF had a much higher incidence of post procedural AF at follow-up when compared to those who were not with rates of 47% vs. 21%, respectively. The data presented becomes significant in two clinical scenarios 1) Long-term post-procedural anticoagulation and 2) the role of pulmonary vein isolation during typical AFL RFA.

Anticoagulation

Anticoagulation therapy should be especially considered for patients with elevated CHADS-VASc scores (≥ 2) who have had AF inducibility during CTI AFL ablation, as the increased risk of future AF implies higher probabilities of thromboembolic stroke. As mentioned above, some studies have shown a 6% cumulative incidence of stroke during mean follow-up of 30 months after ablation for typical AFL, which might be due to the fact that a significant amount of these patients will experience post-procedural AF.^{16, 17}

The 2014 AHA/ACC/HRS Guidelines for the Management of Patients With AF

recommend the same antithrombotic therapy for patients with AFL according to the same risk profile used for AF (Class I, Level of Evidence: C).⁴⁶ Similarly, the 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of AF recommends systemic anticoagulation at least two months following an AF/AFL RFA.⁴⁷ Decisions regarding the continuation of systemic anticoagulation agents more than two months following ablation should be based on the patient's risk factors for stroke and not on the presence or type of AF.⁴⁷ Although, the same principle should be applied for patients undergoing RFA of AFL based on current guidelines,^{46, 47} in clinical practice oral anticoagulation is usually stopped after three months of a successful procedure for AFL.

Prophylactic PVI

Initially Navarrete et al in 2011 assessed whether isolation of the PV at the time of CTI AFL ablation was beneficial. The group that underwent CTI line plus PVI (87%) experience significantly less recurrent arrhythmias than the group with CTI only (87% vs. 44), $P < 0.05$).⁴⁸ The PREVENT-AF study (n: 50) was also a randomized clinical trial of patients in whom only typical AFL had been observed clinically, the addition of PVI to CTI ablation resulted in a marked reduction of new-onset AF during clinical follow-up as assessed by a continuous implantable cardiac monitor (52% vs. 12%; $P = 0.003$).⁴⁹ Further research is required to determine whether inducibility of AF at time of AFL ablation may help in identifying those patients in whom the benefits are most likely to outweigh the risks of a second procedure.

LIMITATIONS

There are many limitations common to retrospective studies and meta-analyses. Many of the included studies have relatively small sample sizes. Studies used different pacing protocols and the induction of AF was performed prior to the CTI line creation in some studies. The occurrence of AF may have been underestimated. Although electrocardiographic documentation of symptomatic arrhythmias was available before ablation and was routinely obtained after ablation, arrhythmia monitoring was variable among studies. Asymptomatic atrial arrhythmias are frequent in this population.

CLINICAL IMPLICATIONS

AF induced by pacing protocols in patients undergoing CTI ablation for common AFL is a strong predictor for future AF. This may be useful to consider in decisions of the intensity of follow-up for arrhythmias and whether to continue long-term anticoagulation after successful typical AFL ablation especially in patients with elevated CHADS-VASc scores (≥ 2). AF inducibility may also be helpful in deciding whether or not to perform prophylactic pulmonary vein isolation for AF during CTI AFL ablation.

REFERENCES

1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA and Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation*. 2004;110:1042-6.
2. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY and Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *European heart journal*. 2006;27:949-53.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV and Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *Jama*. 2001;285:2370-5.

4. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB and Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114:119-25.
5. Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, Hayes J, Eaker E and Vidaillet H. Incidence and predictors of atrial flutter in the general population. *Journal of the American College of Cardiology*. 2000;36:2242-6.
6. O'Callaghan PA, Meara M, Kongsgaard E, Poloniecki J, Luddington L, Foran J, Camm AJ, Rowland E and Ward DE. Symptomatic improvement after radiofrequency catheter ablation for typical atrial flutter. *Heart (British Cardiac Society)*. 2001;86:167-71.
7. Gilligan DM, Zakaib JS, Fuller I, Shepard RK, Dan D, Wood MA, Clemo HF, Stambler BS and Ellenbogen KA. Long-term outcome of patients after successful radiofrequency ablation for typical atrial flutter. *Pacing and clinical electrophysiology : PACE*. 2003;26:53-8.
8. Moreira W, Timmermans C, Wellens HJ, Mizusawa Y, Perez D, Philippens S and Rodriguez LM. Long term outcome of cavotricuspid isthmus cryoablation for the treatment of common atrial flutter in 180 patients: a single center experience. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing*. 2008;21:235-40.
9. Schmieder S, Ndrepepa G, Dong J, Zrenner B, Schreieck J, Schneider MA, Karch MR and Schmitt C. Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. *European heart journal*. 2003;24:956-62.
10. Hsieh MH, Tai CT, Chiang CE, Tsai CF, Yu WC, Chen YJ, Ding YA and Chen SA. Recurrent atrial flutter and atrial fibrillation after catheter ablation of the cavotricuspid isthmus: a very long-term follow-up of 333 patients. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing*. 2002;7:225-31.
11. Ellis SG, Popma JJ, Buchbinder M, Franco I, Leon MB, Kent KM, Pichard AD, Satler LF, Topol EJ and Whitlow PL. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. *Circulation*. 1994;89:882-92.
12. Philippon F, Plumb VJ, Epstein AE and Kay GN. The risk of atrial fibrillation following radiofrequency catheter ablation of atrial flutter. *Circulation*. 1995;92:430-5.
13. Laurent V, Fauchier L, Pierre B, Grimard C and Babuty D. Incidence and predictive factors of atrial fibrillation after ablation of typical atrial flutter. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing*. 2009;24:119-25.
14. Nabar A, Rodriguez LM, Timmermans C, van den Dool A, Smeets JL and Wellens HJ. Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation. *Circulation*. 1999;99:1441-5.
15. Perez FJ, Schubert CM, Parvez B, Pathak V, Ellenbogen KA and Wood MA. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. *Circulation Arrhythmia and electrophysiology*. 2009;2:393-401.

16. Tomson TT, Kapa S, Bala R, Riley MP, Lin D, Epstein AE, Deo R and Dixit S. Risk of stroke and atrial fibrillation after radiofrequency catheter ablation of typical atrial flutter. *Heart rhythm : the official journal of the Heart Rhythm Society*. 2012;9:1779-84.
17. Verma A, Macle L, Cox J and Skanes AC. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. *The Canadian journal of cardiology*. 2011;27:60-6.
18. Brembilla-Perrot B, Girerd N, Sellal JM, Olivier A, Manenti V, Villemain T, Beurrier D, de Chillou C, Louis P, Selton O and de la Chaise AT. Risk of atrial fibrillation after atrial flutter ablation: impact of AF history, gender, and antiarrhythmic drug medication. *Journal of cardiovascular electrophysiology*. 2014;25:813-20.
19. Ellis K, Wazni O, Marrouche N, Martin D, Gillinov M, McCarthy P, Saad EB, Bhargava M, Schweikert R, Saliba W, Bash D, Rossillo A, Erciyes D, Tchou P and Natale A. Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: left-atrial size as an independent predictor of atrial fibrillation recurrence. *Journal of cardiovascular electrophysiology*. 2007;18:799-802.
20. Joza J, Filion KB, Eberg M, Proietti R, Nascimento T, Bernier M, Hadjis T and Essebag V. Prognostic value of atrial fibrillation inducibility after right atrial flutter ablation. *Heart rhythm : the official journal of the Heart Rhythm Society*. 2014;11:1870-6.
21. Da Costa A, Romeyer C, Mourot S, Messier M, Cerisier A, Faure E and Isaaz K. Factors associated with early atrial fibrillation after ablation of common atrial flutter. A single centre prospective study. *European heart journal*. 2002;23:498-506.
22. Bertaglia E, Zoppo F, Bonso A, Proclemer A, Verlato R, Coro L, Mantovan R, D'Este D, Zerbo F, Pascotto P and Northeastern Italian Study on Atrial Flutter Ablation I. Long term follow up of radiofrequency catheter ablation of atrial flutter: clinical course and predictors of atrial fibrillation occurrence. *Heart (British Cardiac Society)*. 2004;90:59-63.
23. Haghjoo M, Salem N, Rafati M and Fazelifar A. Predictors of the atrial fibrillation following catheter ablation of typical atrial flutter. *Res Cardiovasc Med*. 2013;2:90-4.
24. GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. Accessed on April 12th, 2016.
25. Moher D, Liberati A, Tetzlaff J and Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
26. DerSimonian R and Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-88.
27. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629-34.
28. Altman DG and Bland JM. Interaction revisited: the difference between two estimates. *BMJ*. 2003;326:219.
29. Baszko A, Simon RD, Rinaldi A and Gill JS. Occurrence of atrial fibrillation after flutter ablation: the significance of intra-atrial conduction and atrial vulnerability. *J Electrocardiol*. 2003;36:219-25.

30. Joza J, Filion KB, Eberg M, Proietti R, Nascimento T, Bernier M, Hadjis T and Essebag V. Prognostic value of atrial fibrillation inducibility after right atrial flutter ablation. *Heart rhythm : the official journal of the Heart Rhythm Society*. 2014.
31. Paydak H, Kall JG, Burke MC, Rubenstein D, Kopp DE, Verdino RJ and Wilber DJ. Atrial fibrillation after radiofrequency ablation of type I atrial flutter: time to onset, determinants, and clinical course. *Circulation*. 1998;98:315-22.
32. Anselme F, Saoudi N, Poty H, Douillet R and Cribier A. Radiofrequency catheter ablation of common atrial flutter: significance of palpitations and quality-of-life evaluation in patients with proven isthmus block. *Circulation*. 1999;99:534-40.
33. Tai CT, Chen SA, Chiang CE, Lee SH, Wen ZC, Huang JL, Chen YJ, Yu WC, Feng AN, Lin YJ, Ding YA and Chang MS. Long-term outcome of radiofrequency catheter ablation for typical atrial flutter: risk prediction of recurrent arrhythmias. *Journal of cardiovascular electrophysiology*. 1998;9:115-21.
34. Soo Kim; Luigi Di Biase JRREAHDGJNRAGJDEMJDJFJGAKKF. Prediction of Clinical Atrial Fibrillation induced during Typical Atrial Flutter Ablation. 2014; 130: A19766
. *Circulation*. 2014.
35. Chinitz JS, Gerstenfeld EP, Marchlinski FE and Callans DJ. Atrial fibrillation is common after ablation of isolated atrial flutter during long-term follow-up. *Heart rhythm : the official journal of the Heart Rhythm Society*. 2007;4:1029-33.
36. Chen K, Bai R, Deng W, Gao C, Zhang J, Wang X, Wang S, Fu H, Zhao Y, Zhang J, Dong J and Ma C. HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. *Heart rhythm : the official journal of the Heart Rhythm Society*. 2015;12:1483-9.
37. Katritsis D, Iliodromitis E, Fragakis N, Adamopoulos S and Kremastinos D. Ablation therapy of type I atrial flutter may eradicate paroxysmal atrial fibrillation. *Am J Cardiol*. 1996;78:345-7.
38. Schneider R, Lauschke J, Tischer T, Schneider C, Voss W, Moehlenkamp F, Glass A, Diedrich D and Bansch D. Pulmonary vein triggers play an important role in the initiation of atrial flutter: Initial results from the prospective randomized Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial. *Heart rhythm : the official journal of the Heart Rhythm Society*. 2015;12:865-71.
39. Clair WK, Wilkinson WE, McCarthy EA, Page RL and Pritchett EL. Spontaneous occurrence of symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia in untreated patients. *Circulation*. 1993;87:1114-22.
40. Brugada J, Gursay S, Brugada P, Atie J, Guiraudon G and Andries E. Cibenzoline transforms random re-entry into ordered re-entry in the atria. *European heart journal*. 1993;14:267-72.
41. Waldo AL and Cooper TB. Spontaneous onset of type I atrial flutter in patients. *Journal of the American College of Cardiology*. 1996;28:707-12.
42. Watson RM and Josephson ME. Atrial flutter. I. Electrophysiologic substrates and modes of initiation and termination. *Am J Cardiol*. 1980;45:732-41.
43. Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C, Smith PK, Corr PB and Boineau JP. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. *J Thorac Cardiovasc Surg*. 1991;101:406-26.

44. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allessie MA and Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. *Journal of the American College of Cardiology*. 2010;55:725-31.
45. Enriquez A, Sarrias A, Villuendas R, Ali FS, Conde D, Hopman WM, Redfearn DP, Michael K, Simpson C, De Luna AB, Bayes-Genis A and Baranchuk A. New-onset atrial fibrillation after cavotricuspid isthmus ablation: identification of advanced interatrial block is key. *Europace*. 2015;17:1289-93.
46. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW and American College of Cardiology/American Heart Association Task Force on Practice G. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology*. 2014;64:e1-76.
47. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr., Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D, Heart Rhythm Society Task Force on C and Surgical Ablation of Atrial F. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. *Heart rhythm : the official journal of the Heart Rhythm Society*. 2012;9:632-696 e21.
48. Navarrete A, Conte F, Moran M, Ali I and Milikan N. Ablation of atrial fibrillation at the time of cavotricuspid isthmus ablation in patients with atrial flutter without documented atrial fibrillation derives a better long-term benefit. *Journal of cardiovascular electrophysiology*. 2011;22:34-8.
49. Steinberg JS, Romanov A, Musat D, Preminger M, Bayramova S, Artyomenko S, Shabanov V, Losik D, Karaskov A, Shaw RE and Pokushalov E. Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: the PReVENT AF Study I. *Heart rhythm : the official journal of the Heart Rhythm Society*. 2014;11:1567-72.

Figure 1: Selection of studies included in this meta-analysis.

Figure 2. Forest plot of comparison: Inducibility of AF during AFL RFA predicts post-procedural clinical AF. All studies included.

Figure 3: Forest plot of comparison: Inducibility of AF during AFL RFA predicts post-procedural clinical AF. Prospective vs. Retrospective studies.

Figure 4: Funnel Plot for publication bias.

Table 1: Baseline characteristics

Study	Year	Design	# Patients	% Male	Age	Previous AF	LVEF	LA Size	Monitoring	Follow up
Anselme et al.	1999	Retrospective	83	80	60±11	29 (35%)	62±12	37±6	ECG 24-Hour Holter Monitor	27±9
Baszko et al.	2003	Prospective	61	44	48±15	18 (29%)	54±12	NR	24-Hour ECG Monitoring 8-Day Event Recording	16±12
Haghjoo et al.	2013	Retrospective	84	75	49±17	11 (13%)	44±12	38±8	12-lead ECG Holter Monitor	26±22
Hsieh et al.	2002	Retrospective	333	77	63±16	121 (36%)	NR	NR	ECG 24-Hour Holter Monitor Cardiac Event Recorder	29±2
Joza et al.	2014	Retrospective	175	71	63±14.0	82 (47%)	NR	39 (36–45)	48–Hour Holter Monitor Device Interrogations	34±24
Laurent et al.	2009	Retrospective	148	82	65±11	47 (32%)	NR	NR	ECG Holter Monitor Event Monitor	21±8
Paydak et al.	1998	Prospective	110	78	62±14	44 (40%)	50±14	NR	ECG Holter Monitor	20±9
Philippon et al.	1995	Prospective	59	81	62±12	12 (20)	46±0.1	39±6	Standard 12- Lead ECG	13±7
Romero et al.	2016	Retrospective	154	70	70±13	0	48 ±16	NR	ECG Event Monitor Holter Monitor	34±24
Tai et al.	1998	Prospective	144	74	56 ± 18	33 (23%)	NR	NR	Standard 12- Lead ECG 24-Hour Holter Monitor	17±1

Table 2: AF definition and pacing protocols

Study	Year	AF Inducibility Definition	Pacing Protocol
Anselme et al.	1999	Irregular QRS complexes with totally disorganized atrial activity	Not defined
Baszko et al.	2003	Not defined	Baseline pacing with 8 beat drive at a pacing CL of 500 ms, with 1 extrastimulus introduced at decreasing intervals (10 ms decrease) until atrial refractoriness was achieved.
Haghjoo et al.	2013	Not defined	Not defined
Hsieh et al.	2002	Not defined	Baseline pacing with 8 beat drive at 500 and 400 ms, with 1 or 2 extrastimuli; burst pacing for more than 20 beats at progressively shorter cycle lengths until 2:1 atrial capture occurred. Pacing was carried out from the high right atrium, low right atrium and CS.
Joza et al.	2014	Atrial fibrillation lasting >30 seconds	Burst pacing from the anterolateral right atrium and coronary sinus with decremental pacing from 290 to 200 ms or refractoriness over 5 seconds.
Laurent et al.	2009	Atrial fibrillation lasting >30 seconds	Burst pacing (30 seconds) from the high right atrium at a frequency of 200 to 300 bpm by steps of 10 bpm.
Paydak et al.	1998	Atrial fibrillation lasting >30 seconds	Burst pacing from 2 atrial sites (proximal CS and inferolateral tricuspid annulus) at pacing CL of 600, 500 and 400 ms, with progressive 10ms decreases until 2:1 atrial capture
Philippon et al.	1995	Atrial fibrillation lasting >30 seconds	PAS from the HRA or the CS at a pacing CL of 500 ms with 1 or 2 extrastimuli + incremental atrial pacing
Romero et al.	2016	Atrial fibrillation lasting >30 seconds	Atrial burst pacing was carried out to induce AFL before and after ablation. Formal decremental pacing (atrial burst) and atrial pacing at two cycle lengths with single and double extrastimuli to intentionally try to induce AFL.
Tai et al.	1998	Atrial fibrillation lasting >30 seconds	Baseline pacing with 8 beat drive at 600, 500 and 400 ms, with 1 or 2 extrastimuli; burst pacing for more than 20 beats at progressively shorter cycle lengths until 2:1 atrial capture occurred. Pacing was carried out from the high right atrium, low right atrium and CS.

Table 3: Methodology assessment

Author	Year	Selection				Comparability		Outcome			Total
		1	2	3	4	1	2	1	2	3	
Paydak et al	1998	*	*	*	-	*	*	*	*	*	8
Anselme et al	1999	*	*	*	-	*	*	*	-	*	7
Laurent et al	2009	*	*	*	-	*	*	*	*	*	8
Tai et al	1998	*	*	*	-	*	*	*	*	*	8
Baszko et al	2003	*	*	*	-	*	*	*	-	*	7
Haghjoo et al	2013	*	*	*	-	*	*	*	-	*	7
Joza et al	2014	*	*	*	-	*	*	*	-	-	6
Romero et al	2016	*	*	*	*	*	*	*	*	*	9
Hsieh et al	2002	*	*	*	-	*	*	*	*	-	7
Philippon et al	1995	*	*	*	-	*	*	*	-	*	7

Evaluation of article quality based on Newcastle Ottawa Assessment scale. Selection criteria: 1- Representativeness of the exposed cohort, 2-Selection of non exposed cohort, 3- Ascertainment of exposure, 4- Demonstration that outcome of interest was not present at start of study. Comparability criteria: 1- Study controls for the presence of previous AF, 2- Study controls for additional factors. Outcome: 1- Assessment of outcome, 2- Was follow up long enough for outcomes to occur, 3- Adequacy of outcome of controls.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Romero, J;Diaz, JC;Di Biase, L;Kumar, S;Briceno, D;Tedrow, UB;Valencia, CR;Baldinger, SH;Koplan, B;Epstein, LM;John, R;Michaud, GF;Stevenson, WG

Title:

Atrial fibrillation inducibility during cavotricuspid isthmus-dependent atrial flutter ablation as a predictor of clinical atrial fibrillation. A meta-analysis.

Date:

2017-04

Citation:

Romero, J., Diaz, J. C., Di Biase, L., Kumar, S., Briceno, D., Tedrow, U. B., Valencia, C. R., Baldinger, S. H., Koplan, B., Epstein, L. M., John, R., Michaud, G. F. & Stevenson, W. G. (2017). Atrial fibrillation inducibility during cavotricuspid isthmus-dependent atrial flutter ablation as a predictor of clinical atrial fibrillation. A meta-analysis.. J Interv Card Electrophysiol, 48 (3), pp.307-315. <https://doi.org/10.1007/s10840-016-0211-9>.

Persistent Link:

<http://hdl.handle.net/11343/127444>